Foam cell formation

**Foam cell formation** is not a single molecule or receptor but rather describes the biological process by which certain cells—primarily macrophages and vascular smooth muscle cells—accumulate large amounts of lipids, especially modified low-density lipoprotein (LDL), becoming so-called "foam cells." This process is central to the pathogenesis of atherosclerosis. Foam cells arise when monocytes migrate into the arterial intima, differentiate into macrophages, and internalize modified LDL through scavenger receptors such as CD36 and SR-A. Smooth muscle cells can also become foam-like by taking up lipids. The balance between lipid uptake, esterification/storage within cytoplasmic droplets, and efflux determines whether these cells become lipid-laden. Accumulation of these foam cells contributes to plaque growth in arteries—a hallmark event in cardiovascular disease progression[1][2][5][6][7]. **Important note:** "Foam cell formation" refers to a cellular process rather than an individual protein/gene/receptor/enzyme typically considered as therapeutic targets. Therefore: • It is **not itself considered a canonical therapeutic target**, though many therapies aim to modulate this process indirectly. • There is **no standard abbreviation**, nor does it fit typical molecular classification schemes. • The entry should be flagged as **incorrect for use as an individual druggable target**; instead, focus should be on specific molecules involved in this pathway such as scavenger receptors (CD36/SR-A), ABCA1/ABCG1 transporters, or transcription factors like LXR/NF-kappaB[4]. If you require structured information about specific proteins involved in this pathway—such as CD36 or ABCA1—please specify those targets individually.

Other names

Lipid-laden macrophage formationAtherogenic foam cell developmentMacrophage-derived foam cell accumulationVascular smooth muscle cell (VSMC) foam cell formation

- Inhibition of cholesterol synthesis or absorption to reduce substrate for foam cell generation (statins, ezetimibe) - Promotion of cholesterol efflux from macrophages via upregulation of ABCA1/ABCG1 transporters (LXR agonists) *Note*: Mechanisms are indirect; no drug binds "foam cell formation" as a discrete molecular target.